NasdaqCM - Delayed Quote USD
NRx Pharmaceuticals, Inc. (NRXPW)
0.0880
-0.0010
(-1.12%)
At close: 4:00:00 PM EDT
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
0
0
0
0
0
Operating Expense
16,251
18,502
27,587
44,335
94,430
Operating Income
-16,251
-18,502
-27,587
-44,335
-94,430
Net Non Operating Interest Income Expense
21
-186
374
249
-18
Other Income Expense
-7,880
-6,438
-2,937
4,332
1,385
Pretax Income
-24,110
-25,126
-30,150
-39,754
-93,063
Tax Provision
--
--
--
0
0
Net Income Common Stockholders
-24,110
-25,126
-30,159
-39,754
-348,885
Diluted NI Available to Com Stockholders
-24,110
-25,126
-30,159
-39,754
-348,885
Total Operating Income as Reported
-16,351
-18,502
-27,837
-44,335
-115,796
Total Expenses
16,251
18,502
27,587
44,335
94,430
Net Income from Continuing & Discontinued Operation
-24,110
-25,126
-30,150
-39,754
-93,063
Normalized Income
-23,981
-23,469
-29,920
-44,591
-94,448
Interest Income
21
44
494
249
0
Interest Expense
0
230
120
0
18
Net Interest Income
21
-186
374
249
-18
EBIT
-24,110
-24,896
-30,030
-39,754
-93,045
EBITDA
-24,106
-24,891
-30,025
-39,750
-93,043
Reconciled Depreciation
4
5
5
4
2
Net Income from Continuing Operation Net Minority Interest
-24,110
-25,126
-30,150
-39,754
-93,063
Total Unusual Items Excluding Goodwill
-129
-1,657
-230
4,837
1,385
Total Unusual Items
-129
-1,657
-230
4,837
1,385
Normalized EBITDA
-23,977
-23,234
-29,795
-44,587
-94,428
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
-
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
RLFTF Relief Therapeutics Holding SA
2.7000
-2.70%
BCTXW BriaCell Therapeutics Corp.
0.0899
+15.26%
1541.HK IMMUNEONCO-B
13.500
+1.96%
BIOS.BR BioSenic S.A.
0.0021
0.00%
ADXS Ayala Pharmaceuticals, Inc.
0.0406
+28.53%
AGNPF Algernon Pharmaceuticals Inc.
0.0713
+16.89%
HAVLF HAVN Life Sciences Inc.
0.0100
+1,900.00%
AKESF Akeso, Inc.
12.30
+1.57%
CTNM Contineum Therapeutics, Inc.
4.2900
-3.16%
SEER Seer, Inc.
2.0200
-2.42%